The Pharmaceutical Journal Vol 267 No 7166 p373-376
22 September 2001

This article
Reprint
Photocopy

News summary

BNF correction

The section on bisphosphonates in the latest edition of the British National Formulary (no. 42) contains a misleading statement in its discussion of disodium etidronate.

It states that disodium etidronate can impair bone mineralisation (section 6.6.2, p364). Although this is true when giving the drug continously to treat Paget’s disease, the text does not say that it is of little relevance when the drug is used intermittently for the treatment and prevention of osteoporosis.

The electronic versions of the BNF have been corrected and the text will be reworded for the next edition of the book.

Back to Top